Determinants of functional recovery after myocardial infarction of patients treated with bone marrow-derived stem cells after thrombolytic therapy

Heart

Volumn 96, Issue 5, 2010, Pages 362-367

  Miettinen, Johanna A ^a   Ylitalo, Kari ^a   Hedberg, Pirjo ^a   Jokelainen, Jari ^a   Kervinen, Kari ^a   Niemelä, Matti ^a   Säily, Marjaana ^a   Koistinen, Pirjo ^a   Savolainen, Eeva Riitta ^a   Ukkonen, Heikki ^b   Pietilä, Mikko ^b   Juhani Airaksinen, K E ^b   Knuuti, Juhani ^b   Vuolteenaho, Olli ^a   Mäkikallio, Timo H ^a   Huikuri, Heikki V ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN PEPTIDE; CYTOKINE; PLACEBO;

ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DOUBLE BLIND PROCEDURE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL; HOSPITAL ADMISSION; HUMAN; INJECTION; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGISTRATION; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; STEM CELL TRANSPLANTATION; SYMPTOM; TREATMENT OUTCOME;

AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RECOVERY OF FUNCTION; STROKE VOLUME; THROMBOLYTIC THERAPY;

EID: 77649195344     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.171694     Document Type: Article

References (36)

1. Schächinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCAREeAMI trial. J Am Coll Cardiol 2004;44:1690-9.
2. Bartunek J, Vanderheyden M, Vandekerckhove B, et al. Intracoronary injection of CD 133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 2005;112:1178-83.
3. Ge J, Li Y, Qian J, et al. Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction (TCT-STAMI). Heart 2006;92:1764-7.
4. Meluzín J, Mayer J, Groch L, et al. Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function. Am Heart J 2006;152:975. e9-15.
5. Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355: 1210-21.
6. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002;106:1913-18.
7. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004;364:141-8.
8. Janssens S, Theunissen K, Boogaerts M, et al. Bone marrow cell transfer in acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2006;3(Suppl 1):S69-72.
9. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006;355:1199-209.
10. Huikuri HV, Kervinen K, Niemelä M, et al. for the FINCELL Investigators. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008;29:2723-32.
11. Sutherland DR, Anerson L, Keeney M, et al. The ISHAGE guidelines for CD 34+ cell determination by flow cytometry. J Hematother 1996;5:213-26.
12. Hedberg P, Ylitalo K, Puukka M. Highly sensitive determination of C-reactive protein on the Innotrac Aio! immunoanalyzer. Scand J Clin Lab Invest 2004;64:677-85.
13. Hedberg P, Valkama J, Suvanto E, et al. Evaluation of innotrac aio! second-generation cardiac troponin I assay: the main characteristics for routine clinical use. J Autom Methods Manag Chem 2006;2006:39325.
14. Ala-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heterogenity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004;50:1576-88.
15. Ala-Kopsala M, Ruskoaho H, Leppäluoto J, et al. A single assay for cardiac amino-terminal A- and B-type natriuretic peptides. Clin Chem 2005;51:708-18.
16. Yli-Mäyry S, Huikuri HV. Clinical and angiographic prediction of myocardial infarction and recurrence of severe angina during a five-year follow-up after coronary artery bypass grafting. Am J Cadiol 1993;72:1371-5.
17. Berrios VM, Dooner GJ, Nowakowski G, et al. The molecular basis for the cytokine-induced defect in homing and engraftment of hematopoietic stem cells. Exp Hematol 2001;29:1326-35.
18. Behfar A, Zingman LV, Hodgson DM, et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J 2002;16:1558-66.
19. Penicka M, Widimsky P, Kobylka P, et al. Images in cardiovascular medicine. Early tissue distribution of bone marrow mononuclear cells after transcoronary transplantation in a patient with acute myocardial infarction. Circulation 2005;112: e63-5.
20. Bartunek J, Wijns W, Heyndrickx GR, et al. Timing of intracoronary bone-marrow-derived stem cell transplantation after ST-elevation myocardial infarction. Nat Clin Pract Cardiovasc Med 2006;3(Suppl 1):S52-6.
21. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007.
22. Yeh ETH, Zhang S, Wu HD, et al. Transdifferentiation of human peripheral blood CD34 +-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 2003;108:2070-3.
23. Britten MB, Abolmaali ND, Assmus B, et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCAREeAMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation2003;108: 2212-18.
24. Fernández-Avilés F, San Román JA, García-Frade J, et al. Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res2004;95:742-8.
25. Martin-Rendon E, Brunskill SJ, Hyde CJ, et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 2008;29:1807-18.
26. Valente S, Lazzeri C, Chiostri M, et al. NT-proBNP on admission for early risk stratification in STEMI patients submitted to PCI. Relation with extension of STEMI and inflammatory markers. Int J Cardiol2009;132:84-9.
27. Kwon TG, Bae JH, Jeong MH, et al. Korea Acute Myocardial Infarction Registry Investigators. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction who underwent primary percutaneous coronary intervention. Int J Cardiol 2009;133:173-8.
28. Otterstad JE, St John Sutton MG, Froeland GS, et al. Prognostic value of two-dimensional echocardiography and N-terminal proatrial natriuretic peptide following an acute myocardial infarction. Assessment of baseline values (2-7 days) and changes at 3 months in patients with a preserved systolic function. Eur Heart J 2002;23:1011-20.
29. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
30. Puhakka M, Magga J, Hietakorpi S, et al. Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation. J Card Fail 2003;9:325-32.
31. Järemo P, Nilsson O. Interleukin-6 and neutrophils are associated with long-term survival after acute myocardial infarction. Eur J Intern Med2008;19:330-3.
32. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
33. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-time mortality in unstable coronary artery disease. FRISC study group. Fragmin during instability in coronary artery disease. N Engl J Med 2000;343:1139-47.
34. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001;104:1046-52.
35. Kinnaird T, Stabile E, Burnett MS, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms.Circulation 2004;109:1543-9.
36. Heil M, Ziegelhoeffer T, Mees B, et al. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ Res 2004;94:573-4.